

Listing of Claims:

Please cancel claim 33.

1 – 16 (withdrawn).

17. (original) A method of sensitizing tumor cells to chemotherapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell with an effective amount of chemotherapeutic agent.

18. (original) The method of claim 17 in which the tumor cell is exposed to a monoterpene.

19. (original) The method of claim 18 wherein the monoterpene is perillyl alcohol.

20. (original) The method of claim 18 wherein the monoterpene is selected from the group consisting of perillyl alcohol, limonene, carvone, menthol, citral, myrecene and geranyl tigllate.

21. (original) The method of claim 18 wherein the monoterpene is selected from the group consisting of perillyl alcohol, limonene, carvone, citral, myrecene, and geranyl tigllate.

22. (original) The method of claim 17 wherein the tumor cell is a malignant glioma cell.

23. (original) The method of claim 17 wherein the tumor cell is selected from the group consisting of colon, pancreatic and prostate cells.

24. (original) The method of claim 17 wherein the cell is exposed to the monoterpene or sesquiterpene before and during chemotherapy.

25. (original) The method of claim 17 wherein the cell is exposed to a monoterpene.

26. (currently amended) A method of sensitizing tumor cells to cytokines ~~immunomodulatory agents~~, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cells with the immunomodulatory agent.

27. (original) The method of claim 26 wherein the monoterpene is perillyl alcohol.

28. (original) The method of claim 26 wherein the monoterpene is selected from the group consisting of perillyl alcohol, limonene, carvone, menthol, citral, myrecene and geranyl tigllate.

29. (original) The method of claim 26 wherein the monoterpene is selected from the group consisting of perillyl alcohol, limonene, carvone, citral, myrcene, and geranyl tigllate.

30. (original) The method of claim 26 wherein the tumor cell is a malignant glioma cell.


31. (original) The method of claim 26 wherein the cell is exposed to the monoterpene or sesquiterpene before or during therapy.

32. (original) The method of claim 31 wherein the cell is exposed to a monoterpene.

33. (canceled)

Respectfully submitted,

Michael N. Gould, et al.

By: 

Jean C. Baker
Quarles & Brady LLP
Reg. No. 35,433
Attorney for Applicant
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
414/277-5709